Compare McKesson Corporation (MCK) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nutrien Ltd — how do they compare? McKesson Corporation trades at $823.86 (market cap $97.35B), while Nutrien Ltd trades at $66.75 (market cap $31.67B). The key difference: McKesson Corporation is far larger — about 3.1× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| MCK | NTR | |
|---|---|---|
Market Cap | $97.35B | $31.67B |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $83.94 |
52-Week Low | $659.01 | $53.64 |
Enterprise Value | $101.98B | $44.84B |
Dividend Yield | 0.39% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Nutrien (NTR) trades at $66.40, down 1.31% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, and revenue trending upward to $26.89B in 2025. Valuation ratios appear attractive with a P/E of 13.7 and P/S of 1.17. Analyst sentiment is positive with a consensus price target of $77.67, representing 17% upside, and 61% of analysts rate it a Buy.
The outlook for Nutrien is favorable due to strong fertilizer demand and cost management, though risks include volatile input costs and competitive pressures. With solid cash flow from operations and a dividend payout, the stock offers value and income potential, but investors should monitor global agricultural trends and energy market impacts on margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
